ArticleCase reports in transplantation2026
Unmasking the Threat: Acute Hepatitis E Virus Infection in a Liver Transplant Recipient.
Article in Case reports in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unmasking the Threat: Acute Hepatitis E Virus Infection in a Liver Transplant Recipient.Case reports in transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) infection is an increasingly recognized cause of acute and chronic hepatitis in immunosuppressed individuals, including solid organ transplant recipients. Although typically self-limited in immunocompetent hosts, HEV infection in transplant recipients may lead to persistent viremia, accelerated fibrosis, and graft dysfunction. We report the case of a 47-year-old man who underwent deceased donor liver transplantation for decompensated metabolic-associated steatohepatitis cirrhosis. Five months post-transplant, he was found to have rising liver enzymes during routine monitoring. Imaging and two liver biopsies showed no evidence of acute cellular rejection. Subsequent evaluation revealed positive HEV IgM and detectable HEV RNA with a viral load of 5.5 million IU/mL. Reduction of immunosuppression and initiation of ribavirin therapy resulted in rapid biochemical improvement and complete viral clearance. HEV RNA remained undetectable at the end of therapy and during extended follow-up. This case highlights the importance of early consideration of HEV infection in liver transplant recipients with unexplained liver enzyme abnormalities. Prompt diagnosis and guideline-concordant management can prevent progression to chronic infection and preserve graft function.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.